Effect of Propranolol on Hyperthermia Secondary to Paroxysmal Sympathetic Hyperactivity in Critically Ill Patients With Traumatic Brain Injury
- 26 July 2025
- journal article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (3) , 229-237
Abstract
Background: Patients with traumatic brain injury (TBI) may develop paroxysmal sympathetic hyperactivity (PSH), a syndrome manifesting as cyclic increases in vital signs and motor activity. Previous studies show propranolol mitigating sympathetic symptoms and negative outcomes, but few reports assess its effect on body temperature. Objective: The purpose of this study was to determine if propranolol attenuates hyperthermia secondary to PSH in patients with TBI. Methods: This study evaluated febrile patients with TBI treated with propranolol. The primary outcome was the difference in maximum (Tmax), minimum (Tmin), and average (Tavg) daily temperatures and temperature variability (Tvar). Secondary outcomes included similar evaluation of heart rate (HR) and mean arterial pressure (MAP), differences in a modified clinical features scale (mCFS), and number of infectious work-ups before and after propranolol initiation. Data were collected one day before, the day of, and 3 days after propranolol initiation. Repeated measures analysis of variance (ANOVA) was used to evaluate vital sign differences among days of therapy. Post-hoc Tukey’s tests were performed to identify between-day differences if they existed. Results: Fifty-nine patients were included. The majority were male (76.3%) and had a severe TBI (78.0%). Tmax, Tmin, Tavg, and Tvar were all not different between Day −1 and Day 3. Tmax decreased from 38.6 ± 0.11°C on Day 0 (the day of propranolol initiation) to 38.3 ± 0.14°C on Day 3 ( P = 0.22). Maximum and average HRs were significantly decreased after propranolol initiation on Day 3 ( P < 0.001) and on Days 2 ( P = 0.04) and 3 ( P = 0.01), respectively. Changes in MAP were not statistically significant. The mCFS and number of infectious work-ups were significantly lower after propranolol initiation. Conclusion and Relevance: Temperature was not significantly decreased after propranolol initiation in patients with TBI and hyperthermia; however, HR and mCFS were significantly lower. Larger studies are needed to characterize the effect of propranolol on temperature in patients with PSH.Keywords
This publication has 30 references indexed in Scilit:
- Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICUCritical Care Medicine, 2023
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021Critical Care Medicine, 2021
- The Effect of Early Sedation With Dexmedetomidine on Body Temperature in Critically Ill Patients*Critical Care Medicine, 2021
- Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: infection and sepsisBritish Journal of Anaesthesia, 2019
- Paroxysmal sympathetic hyperactivity: the storm after acute brain injuryThe Lancet Neurology, 2017
- Catecholamines and Paroxysmal Sympathetic Hyperactivity after Traumatic Brain InjuryJournal of Neurotrauma, 2017
- Paroxysmal Sympathetic Hyperactivity after Acquired Brain Injury: Consensus on Conceptual Definition, Nomenclature, and Diagnostic CriteriaJournal of Neurotrauma, 2014
- Paroxysmal Sympathetic Hyperactivity after Traumatic Brain Injury: Clinical and Prognostic ImplicationsJournal of Neurotrauma, 2012
- The Epidemiology and Impact of Traumatic Brain InjuryJournal of Head Trauma Rehabilitation, 2006
- Fever of central origin in traumatic brain injury controlled with propranololArchives of Physical Medicine and Rehabilitation, 1994